The efficacy and safety of immune checkpoint inhibitors for patients with EGFR‐mutated non‐small cell lung cancer who progressed on EGFR tyrosine‐kinase inhibitor therapy: A systematic review and network meta‐analysis

BACKGROUND: Non‐small cell lung cancer (NSCLC) patients harboring epidermal growth factor receptor (EGFR)‐mutated who progressed on EGFR tyrosine‐kinase inhibitor (EGFR‐TKI) therapy have limited therapeutic options. There is still no consensus on the role of immune checkpoint inhibitors (ICIs) in NS...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Zhen, Zhou, Fang, Xu, Shan, Wang, Kang, Ding, Huan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
REVIEW
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557893/
https://www.ncbi.nlm.nih.gov/pubmed/37584242
http://dx.doi.org/10.1002/cam4.6453

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10557893/
https://www.ncbi.nlm.nih.gov/pubmed/37584242
http://dx.doi.org/10.1002/cam4.6453

Ejemplares similares